Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery - Yahoo Finance

Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery  Yahoo Finance

Technology produces novel heavy chain-only antibodies for bi-specific, single domain antibodies or CAR-Ts.



Comments

Popular posts from this blog

Keto crotch: Is it real and how to treat it

Shave your pubic hair if you want, but not at these times

What is Ivermectin, the drug Goa will give to all adults to combat Covid-19 - India Today